How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

477 results for

Progestin Androgenic Activity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. The RCT of Acupuncture on PCOS Combined With IR

will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Drug: Placebo metformin Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month. Other Name: placebo Dimethylbiguanide Active Comparator: sham acupuncture + metformin Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use (...) h excited test (after 60 min)) ⑤ Suspected androgen secreting adrenal or ovarian tumor. Use of hormonal or other medication including Chinese Herbal prescriptions which may affect the outcome the last 2 months. Receiving acupuncture in the past 2 months. Within 6 weeks pregnancy. Post-abortion or postpartum within the past 6 weeks. Breastfeeding within the last 4 months. Not willing to give written consent to the study. Having a bariatric surgery procedure within the past 12 months or being

2015 Clinical Trials

162. The Clinical Trial of Acupuncture Pre-treatment on PCOS

following progestin, one time per day.Participants are treated for up to 4 cycles. Other Name: Letrozole(Femara, Novartis Pharmaceuticals) Active Comparator: Letrozole LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles. Drug: Letrozole Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following (...) Estimated Study Completion Date : December 2017 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Pre-treatment acupuncture + letrozole A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during

2015 Clinical Trials

163. Synthetic vs Natural Estrogen in Combined Oral Contraception

related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Synthetic estrogen + progestin Ethinyl estradiol / dienogest Drug: Ethinyl estradiol / dienogest One tablet orally for 9 weeks, continuous use Other Name: Valette, ATC code G03AA Experimental: Natural estrogen + progestin Estradiol valerate / dienogest Drug: Estradiol valerate / dienogest One tablet orally for 9 weeks, continuous use Other Name: Qlaira, ATC code G03AB08 Active Comparator: Progestin (...) by (Responsible Party): Annina Haverinen, Helsinki University Central Hospital Study Details Study Description Go to Brief Summary: The main objective of the study is to compare the metabolic effects of natural estradiol and synthetic ethinylestradiol used in combined oral contraception in healthy women. A progestin-only preparation will be used in comparison. The main goal is to study the effects on glucose metabolism, coagulation and a markers of chronic inflammation (such as hs-CRP). Our hypothesis

2015 Clinical Trials

164. Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02354001 Locations Layout table for location information (...) ) and a score of 4 (moderate) or more on two or more of the following PANSS items: delusions, hallucinatory behaviour, conceptual disorganization or suspiciousness. No abnormality observed during physical breast examination. Documented normal PAP smear and pelvic examination in the preceding two years. Exclusion Criteria: Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event

2015 Clinical Trials

165. Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women (TSEC)

be a precursor to cancer. DUAVEE™ uses bazedoxifene, a selective estrogen receptor modulator (SERM), in place of a progestin to help protect the uterus against thickening of the uterus that may result from estrogens alone. In this study, you will get either DUAVEE™ or the placebo (a "dummy pill" that may look like medicine but contains no active medication) first and then switch to the other pill. Condition or disease Intervention/treatment Phase Menopause Drug: TSEC (Tissue-selective estrogen complexes (...) (the main female hormone made by the ovaries) and bazedoxifene, which is FDA approved. For over 60 years, estrogens have been used as hormonal treatments to help manage hot flashes and help prevent postmenopausal bone loss. But in the treatment of postmenopausal women, the use of estrogens alone can increase the risk of developing cancer of the uterus. So estrogens have been traditionally paired with a progestin to decrease the risk of hyperplasia (the thickening of the lining of the uterus), which can

2014 Clinical Trials

166. Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women

of testosterone therapy for the treatment of hypoactive sexual desire disorder (HSDD) in women has been demonstrated in studies including naturally and surgically menopausal women, either alone or in combination with estrogen, with or without progestin therapy. Condition or disease Intervention/treatment Phase Sex Behavior Drug: Biolipid B2 (blanked/placebo) Drug: Testosterone, Transdermal, Behavior Phase 2 Detailed Description: Recent studies have reported an increase in the number of satisfactory sexual (...) : Biolipid B2 (blanked/placebo) the intervention will be the comparison effects of both emulsions Other Names: Biolipid B2 0.5% testosterone, Evidence, Fortaleza, Brazil Biolipid B2 0.5% testosterone, Pharmacom, São Paulo, Brazil Drug: Testosterone, Transdermal, Behavior Transdermal 0.5% testosterone Biolipid/B2 Other Name: Transdermal testosterone Biolipid/B2 Active Comparator: Testosterone, Transdermal, Behavior Testosterone 0.5%, daily, 3 months Drug: Biolipid B2 (blanked/placebo) the intervention

2014 Clinical Trials

167. Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB

of a structural stable endometrium) and to prevent endometrial hyperplasia. The two main treatment options are estrogen-progestin therapy and progestin therapy. Women who are sexually active and not immediately prepared to pursue pregnancy are best manage by estrogen-progestin treatment especially combined oral contraceptive pills (COCs) but in perimenopausal women, obese women or women who can't tolerate COCs or have contraindications in using COCs, cyclic progestin will be the treatment of choice. Common (...) used progestin in anovulatory DUB is medroxyprogesterone acetate (MPA) 5-10 mg/day for 10-14 days each month. This progestin has strong progestogenic effect but has some undesirable effect such as glucocorticoid effect, mineralocorticoid effect and androgenic effect. Long term using this progestin especially in obese women or perimenopausal women who have risk for diabetes mellitus and dyslipidemia may be negative effect to glucose and lipid metabolism. DSG is the third generation progestin

2014 Clinical Trials

168. Radium-223 in Combination With Enzalutamide

All anti-androgen therapy (including bicalutamide) is excluded within 6 weeks prior to first dose of study drug. Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (eg, finasteride or dutasteride), must be discontinued 2 weeks before the first dose of study drug. [Bisphosphonates and Denosumab are allowed concomitant medications]. Prior chemotherapy for prostate cancer (...) validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02225704 Recruitment Status : Active, not recruiting First Posted : August 26, 2014 Last Update Posted : July 24, 2018 Sponsor: Cancer Trials Ireland Information provided by (Responsible Party): Cancer Trials Ireland Study Details Study Description Go to Brief Summary: This study

2014 Clinical Trials

169. Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

endometrial biopsy. Subjects who have a Body Mass Index (BMI) less than or equal to 38 kg/m2. BMI values should be rounded to the nearest integer (ex. 32.4 rounds down to 32, while 26.5 rounds up to 27). In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study. Exclusion Criteria: Use of the following: Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening visit 1A (can enter washout (...) from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12 Secondary Outcome Measures : Secondary Efficacy Endpoints - Vaginal Superficial Cells [ Time Frame: Baseline and Week 2 ] • Change from Baseline to Week 2 in the percentage of vaginal

2014 Clinical Trials

170. CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Responsive-HER2neg and TN-ARpos Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02067741 Recruitment Status : Active, not recruiting First Posted : February 20, 2014 Last Update Posted : January 23, 2019 Sponsor: Swiss Group for Clinical Cancer Research Information provided by (Responsible (...) , interaction with the AR and the aromatase enzyme may have a higher activity than drugs with a single mechanism and might offer the possibility of non-chemotherapy based endocrine therapy to the limited treatment options in TN-ARpos BC. Transdermal application of CR1447 might have the advantage to continuously release of 4-OHT into the blood stream, thus omitting a first pass effect. In Phase II the main objective is to assess activity and to determine the efficacy and tolerability of CR1447. Phase II

2014 Clinical Trials

171. Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

hydrochloride). SECONDARY OBJECTIVES: I. To determine the safety and tolerability of mifepristone in combination with carboplatin and gemcitabine. II. To describe the toxicities seen with carboplatin, gemcitabine, and mifepristone combination therapy. TERTIARY OBJECTIVES: I. To correlate expression of biomarkers (e.g. glucocorticoid receptor [GR], androgen receptor [AR], estrogen receptor [ER], and progesterone receptor [PR]) with treatment outcomes. II. To correlate serum and intratumoral mifepristone (...) >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal Morning cortisol >= institutional normal If a woman is of childbearing potential, a negative serum or urine pregnancy test is required; women of child-bearing potential and men who are sexually active must agree to use birth control such as barrier method of birth control, abstinence, or else be surgically sterile (tubal ligation, hysterectomy or partner with confirmed vasectomy) prior to study entry

2014 Clinical Trials

172. Kaempferol Exhibits Progestogenic Effects in Ovariectomized Rats (PubMed)

, the ability of kaempferol to block genistein action in the uterus was investigated. Analyses of proliferation, steroid receptor expression, and induction of well-established PR-regulated targets Areg and Hand2 were completed using histological analysis and qPCR gene induction experiments. In addition, kaempferol in silico binding analysis was completed for PR. The activation of estrogen and androgen receptor signalling was determined in vitro.Molecular docking analysis confirmed that kaempferol adopts (...) poses that are consistent with occupying the ligand-binding pocket of PRA. Kaempferol induced expression of PR regulated transcriptional targets in the ovariectomized rat uteri, including Hand2 and Areg. Consistent with progesterone-l ke activity, kaempferol attenuated genistein-induced uterine luminal epithelial proliferation without increasing uterine weight. Kaempferol signalled without down regulating PR expression in vitro and in vivo and without activating estrogen and androgen receptors.Taken

Full Text available with Trip Pro

2014 Journal of steroids & hormonal science

173. Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception (PubMed)

Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception Testosterone (T), alone or in combination with progestin, provides a promising approach to hormonal male contraception. Its principle relies on enhanced negative feedback of exogenous T to suppress gonadotropins, thereby blocking the testicular T production needed for spermatogenesis, while simultaneously maintaining the extragonadal androgen actions (...) , such as potency and libido, to avoid hypogonadism. A serious drawback of the treatment is that a significant proportion of men do not reach azoospermia or severe oligozoospermia, commensurate with contraceptive efficacy. We tested here, using hypogonadal luteinizing hormone/choriongonadotropin receptor (LHCGR) knockout (LHR(-/-)) mice, the basic principle of the T-based male contraceptive method, that a specific T dose could maintain extragonadal androgen actions without simultaneously activating

Full Text available with Trip Pro

2014 The FASEB Journal

174. Breast Cancer

tissue density (mammographic).[ ] Estrogen (endogenous).[ - ] Menstrual history (early menarche/late menopause).[ , ] Nulliparity. Older age at first birth. Hormone therapy history. Combination estrogen plus progestin hormone replacement therapy. Obesity (postmenopausal).[ ] Personal history of breast cancer.[ ] Personal history of benign breast disease (BBD) (proliferative forms of BBD).[ - ] Radiation exposure to breast/chest.[ ] Age-specific risk estimates are available to help counsel and design (...) ): 571-80, 2012. Key TJ, Appleby PN, Reeves GK, et al.: Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105 (5): 709-22, 2011. Kaaks R, Rinaldi S, Key TJ, et al.: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12 (4): 1071-82, 2005. Kaaks R, Berrino F, Key T, et al.: Serum sex steroids in premenopausal women and breast cancer

2012 PDQ - NCI's Comprehensive Cancer Database

175. Genetics of Breast and Ovarian Cancer

(95% CI, 1.21–1.49) for women who had used HRT for 5 or more years after menopause.[ ] The (NCT00000611), a randomized controlled trial of about 160,000 postmenopausal women, investigated the risks and benefits of HRT. The estrogen-plus-progestin arm of the study, in which more than 16,000 women were randomly assigned to receive combined HRT or placebo, was halted early because health risks exceeded benefits.[ , ] Adverse outcomes prompting closure included significant increase in both total (245 (...) vs. 185 cases) and invasive (199 vs. 150 cases) breast cancers (RR, 1.24; 95% CI, 1.02–1.5, P < . 001) and increased risks of coronary heart disease, stroke, and pulmonary embolism. Similar findings were seen in the estrogen-progestin arm of the prospective observational Million Women’s Study in the United Kingdom.[ ] The risk of breast cancer was not elevated, however, in women randomly assigned to estrogen-only versus placebo in the WHI study (RR, 0.77; 95% CI, 0.59–1.01). Eligibility

2012 PDQ - NCI's Comprehensive Cancer Database

176. Breast Cancer Prevention

of Breast Cancer Combination hormone therapy Based on solid evidence, combination hormone therapy (HT) (estrogen-progestin) is associated with an increased risk of developing breast cancer. Magnitude of Effect : Approximately a 26% increase in incidence of invasive breast cancer; the number needed to produce one excess breast cancer is 237. Study Design : Randomized controlled trials (RCTs). Furthermore, cohort and ecological studies show that cessation of combination HT is associated with a decrease (...) , tamoxifen and raloxifene reduce the incidence of breast cancer in postmenopausal women, and tamoxifen reduces the risk of breast cancer in high-risk premenopausal women. The effects observed for tamoxifen and raloxifene show persistence several years after active treatment is discontinued, with longer duration of effect noted for tamoxifen than for raloxifene.[ ] All fractures were reduced by SERMs, primarily noted with raloxifene but not with tamoxifen. Reductions in vertebral fractures (34% reduction

2012 PDQ - NCI's Comprehensive Cancer Database

177. Ovarian Cancer (Overview)

with abnormal gonads. They may have a 46XY karyotype with pure gonadal dysgenesis or androgen insensitivity syndrome, or, they may have a 45X, 46XY karyotype with mixed gonadal dysgenesis. Dysgerminomas may be large and usually are solid, with a smooth external surface and a fleshy pink-tan color inside. The majority are confined to the ovary at diagnosis, but approximately 25% of otherwise stage I dysgerminomas have lymph node metastasis. For more information, see . Cystic teratoma Teratomas are germ cell (...) and Sertoli-Leydig cell tumors less so, they behave in a much less malignant fashion than epithelial ovarian cancers. Benign tumors in the group include thecoma and fibroma. Granulosa cell tumors and pure Sertoli cell tumors commonly secrete estrogen, while Leydig cell tumors and combined Sertoli-Leydig tumors often secrete androgens. Granulosa cell tumor This is the most common malignant sex-cord stromal tumor. Ninety percent of granulosa cell tumors are stage I at the time of diagnosis. This tumor

2014 eMedicine.com

178. Osteoporosis (Overview)

trauma Pain is localized to a specific, identifiable, vertebral level in the midthoracic to lower thoracic or upper lumbar spine The pain is described variably as sharp, nagging, or dull; movement may exacerbate pain; in some cases, pain radiates to the abdomen Pain is often accompanied by paravertebral muscle spasms exacerbated by activity and decreased by lying supine Patients often remain motionless in bed because of fear of causing an exacerbation of pain Acute pain usually resolves after 4-6 (...) detail. Management Lifestyle modification for prevention of osteoporotic fractures includes the following [ ] : Increasing weight-bearing and muscle-strengthening exercise Ensuring optimum calcium and vitamin D intake as an adjunct to active antifracture therapy The NOF recommends that pharmacologic therapy should be reserved for postmenopausal women and men aged 50 years or older who present with the following [ ] : A hip or vertebral fracture (vertebral fractures may be clinical or morphometric [eg

2014 eMedicine.com

179. Amenorrhea, Primary (Follow-up)

Amenorrhea, Primary (Follow-up) Amenorrhea Treatment & Management: Approach Considerations, Treatment of Common Causes, Diet and Activity Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjUyOTI4LXRyZWF0bWVudA (...) be the restoration of ovulatory cycles. If ovulatory cycles are not spontaneously restored, estrogen-progestin therapy is indicated. Osteoporosis prevention Evidence is mounting that loss of menstrual regularity, especially if related to hypogonadotropic hypogonadism, is a risk factor for later development of osteoporosis and hip fractures. Patients and clinicians need to view the ovary as an important endocrine organ that helps to maintain healthy bones. Excessive delay in the evaluation and treatment

2014 eMedicine.com

180. Angioedema (Follow-up)

or intraoral surgery and bronchoscopy or endoscopy; endotracheal intubation; and manipulation of the upper airway or pharynx Before beginning long-term prophylaxis with androgens, obtain a complete blood count (CBC), urinalysis, liver function tests (LFTs), lipid profile, and liver ultrasonography, as well as assess the patient for cardiac risk factors; during use of androgens for long-term prophylaxis and for 6 months after cessation of therapy, monitor the patient’s CBC, urinalysis, lipid profile, LFTs (...) to relieve symptoms adequately. Thus, H1 antihistamines may be given in combination with H2 antihistamines. Most often, the initial dose is given at bedtime or late in the evening. Many patients may become more tolerant to the sedative effects of the first-generation antihistamine after a few days of treatment. The dosage can be gradually titrated toward better symptom control as tolerated. Doxepin is a tricyclic antidepressant (TCA) that has potent H1-blocking activity. For this reason, it has been used

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>